A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the safety and tolerance of low-dose versus high-dose cysteamine administered
concurrently with zidovudine (AZT). To determine the pharmacokinetics and effects on immune
function and viral load in patients receiving these drug regimens.